Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nebivolol
Drug ID BADD_D01541
Description Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity.[A182579] Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol].[A182579] Nebivolol and other beta blockers are generally not first line therapies as many patients are first treated with thiazide diuretics.[A182594] Nebivolol was granted FDA approval on 17 December 2007.[L7985]
Indications and Usage Nebivolol is indicated to treat hypertension.[A2762,A182579,L7985,L7988]
Marketing Status approved; investigational
ATC Code C07AB12
DrugBank ID DB04861
KEGG ID D05127
MeSH ID D000068577
PubChem ID 71301
TTD Drug ID D0Z1UA
NDC Product Code 13668-356; 31722-586; 51407-486; 62559-276; 13668-354; 51407-483; 59651-137; 62559-278; 0904-7226; 62559-275; 63629-9589; 70756-025; 71209-058; 72241-033; 72241-034; 72241-035; 62559-277; 0904-7189; 70756-291; 71209-059; 13668-355; 31722-587; 43547-527; 50090-5708; 50090-5761; 50090-5775; 59651-140; 63629-9423; 63629-9424; 70756-292; 27241-182; 51407-485; 59651-139; 67877-391; 67877-392; 67877-393; 70518-3527; 71209-060; 72241-032; 65977-0048; 60687-641; 60687-652; 67877-390; 70756-293; 0904-7190; 0904-7225; 27241-179; 27241-180; 31722-585; 43547-524; 43547-525; 51407-484; 71209-061; 13668-353; 27241-181; 31722-588; 50090-5752; 59651-138
UNII 030Y90569U
Synonyms Nebivolol | Alpha,Alpha'-(Iminobis(Methylene))bis(6-Fluoro-3,4-dihydro)-2H-1-benzopyran-2-methanol | Bystolic | Nebilet | Silostar | Nebivolol Hydrochloride | Hydrochloride, Nebivolol | R 67555 | 67555, R | R-67555 | R67555 | Lobivon
Chemical Information
Molecular Formula C22H25F2NO4
CAS Registry Number 99200-09-6
SMILES C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.0010.000252%Not Available
Abdominal pain07.01.05.0020.000642%
Acute pulmonary oedema02.05.02.004; 22.01.03.005--Not Available
Alanine aminotransferase increased13.03.04.005--
Alopecia23.02.02.0010.001032%
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.0090.000172%Not Available
Aspartate aminotransferase increased13.03.04.011--
Asthenia08.01.01.0010.000309%Not Available
Atrial fibrillation02.03.03.0020.000115%
Atrioventricular block02.03.01.002--Not Available
Atrioventricular block complete02.03.01.0030.000115%
Blood bilirubin increased13.03.04.018--
Blood triglycerides increased13.12.03.001--Not Available
Blood urea increased13.13.01.006--Not Available
Blood uric acid increased13.02.04.001--Not Available
Bradycardia02.03.02.0020.001444%Not Available
Bronchospasm22.03.01.004; 10.01.03.012--
Bundle branch block02.03.01.0090.001364%Not Available
Chest discomfort22.12.02.002; 08.01.08.019; 02.02.02.0090.000115%Not Available
Chest pain22.12.02.003; 02.02.02.011; 08.01.08.0020.000585%Not Available
Confusional state19.13.01.001; 17.02.03.0050.000447%
Cough22.02.03.0010.000837%
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.0030.001123%
Drug abuse19.07.06.0100.000115%Not Available
Drug hypersensitivity10.01.01.0010.001948%Not Available
Drug ineffective08.06.01.0060.002178%Not Available
Dysgeusia17.02.07.003; 07.14.03.0010.000585%
Dyspnoea02.11.05.003; 22.02.01.0040.000619%
The 1th Page    1 2 3    Next   Last    Total 3 Pages